147 related articles for article (PubMed ID: 38520571)
1. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
Straube C; Combs SE; Bernhardt D; Gempt J; Meyer B; Zimmer C; Schmidt-Graf F; Vajkoczy P; Grün A; Ehret F; Zips D; Kaul D
J Neurooncol; 2024 May; 168(1):49-56. PubMed ID: 38520571
[TBL] [Abstract][Full Text] [Related]
2. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
3. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
[TBL] [Abstract][Full Text] [Related]
4. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
Brandes AA; Franceschi E; Tosoni A; Bartolini S; Bacci A; Agati R; Ghimenton C; Turazzi S; Talacchi A; Skrap M; Marucci G; Volpin L; Morandi L; Pizzolitto S; Gardiman M; Andreoli A; Calbucci F; Ermani M
Neuro Oncol; 2010 Mar; 12(3):283-8. PubMed ID: 20167816
[TBL] [Abstract][Full Text] [Related]
5. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
7. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
8. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
9. Role of
Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
[TBL] [Abstract][Full Text] [Related]
10. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
13. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
[TBL] [Abstract][Full Text] [Related]
14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors influencing survival following re-resection for isocitrate dehydrogenase (IDH) -wildtype glioblastoma multiforme - Data from a national neuro-oncology registry.
Hennessy MA; Coyne ZL; O'Halloran PJ; Mullally W; Dablouk M; MacNally S; Morris PG
J Clin Neurosci; 2022 Jan; 95():142-150. PubMed ID: 34929638
[TBL] [Abstract][Full Text] [Related]
16. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
17. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
[TBL] [Abstract][Full Text] [Related]
18. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?
Heiland DH; Haaker G; Watzlawick R; Delev D; Masalha W; Franco P; Machein M; Staszewski O; Oelhke O; Nicolay NH; Schnell O
J Neurooncol; 2018 Nov; 140(2):385-391. PubMed ID: 30076585
[TBL] [Abstract][Full Text] [Related]
19. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
[TBL] [Abstract][Full Text] [Related]
20. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.
Chun SJ; Park SH; Park CK; Kim JW; Kim TM; Choi SH; Lee ST; Kim IH
Radiother Oncol; 2018 Aug; 128(2):254-259. PubMed ID: 29937212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]